

PATENT ASSIGNMENT

Electronic Version v1.1
 Stylesheet Version v1.1

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT
CONVEYING PARTY DATA	
Name	Execution Date
Novartis AG	11/08/2011
RECEIVING PARTY DATA	
Name:	Astex Therapeutics, LTD
Street Address:	436 Cambridge Science Park, Milton Road
City:	Cambridge
State/Country:	UNITED KINGDOM
PROPERTY NUMBERS Total: 1	
Property Type	Number
Application Number:	13882353
CORRESPONDENCE DATA	
Fax Number:	
<i>Correspondence will be sent via US Mail when the fax attempt is unsuccessful.</i>	
Phone:	8627780705
Email:	cindy.klepacky@novartis.com
Correspondent Name:	Cindy Klepacky
Address Line 1:	One Health Plaza
Address Line 4:	East Hanover, NEW JERSEY 07936
ATTORNEY DOCKET NUMBER:	PAT054441-US-PCT
NAME OF SUBMITTER:	Cindy Klepacky
Signature:	/Cindy Klepacky/
Date:	05/01/2013
Total Attachments: 4 source=Novartis AG_and_Astex_Therapeutics#page1.tif source=Novartis AG_and_Astex_Therapeutics#page2.tif source=Novartis AG_and_Astex_Therapeutics#page3.tif source=Novartis AG_and_Astex_Therapeutics#page4.tif	

CH \$40.00 13882353

ASSIGNMENT

THIS ASSIGNMENT, effective 8 November 2011, made by NOVARTIS AG, a corporation of Switzerland, having a principal place of business at Lichtstrasse 35, CH-4056 Basel, Switzerland,

WITNESSETH: That,

WHEREAS, NOVARTIS AG, hereinafter referred to as *ASSIGNOR*, has previously acquired the right, title, and interest in and to certain new and useful improvements in

SALT(S) OF 7-CYCLOPENTYL-2-(5-PIPERAZIN-1-YL-PYRIDIN-2-YLAMINO)-7H-PYRROLO[2,3-D]PYRIMIDINE-6-CARBOXYLIC ACID DIMETHYLAMIDE AND PROCESSES OF MAKING THEREOF

and filed in the Office on , 20 and accorded Application Number and/or filed as a PCT International Application on , 2011 and accorded International Patent Application Number PCT/US2011/ ; and/or filed in the United States Patent and Trademark Office on 10 November 2010 and accorded Application Number 61/412,064

Both the international application and the U.S. Provisional application will hereinafter be referred to as the subject applications.

WHEREAS, *ASTEX THERAPEUTICS, LTD.*, a corporation of England and Wales, having its principal place of business at 436 Cambridge Science Park, Milton Road, Cambridge, CB4 0QA, UK, hereinafter referred to as *ASSIGNEE*, is desirous of acquiring fifty percent (50%) of the rights, title, and interest in and to said invention as described in said applications, and in and to any and all Letters Patent which shall be granted based upon this international patent application in the United States of America and all foreign countries; and

WHEREAS, the parties have agreed to the Assignment hereinafter set forth;

NOW, THEREFORE, To All Whom It May Concern, be it known that for good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, the above *ASSIGNOR* has sold and by these presents does hereby sell, assign, transfer, and convey unto the said *ASSIGNEE*, its successors and assigns, a fifty percent (50%) right, title, and undivided interest in and to said subject applications and said Patents, and the inventions represented

thereby, and any and all continuations, continuations-in-part, or divisions thereof, and any and all Letters Patent or reissues, reexaminations, or extensions thereof which may be granted therefore or thereon, for the full end of the term for which said Letters Patent may be granted, together with the right to claim priority in all foreign countries in accordance with the International Convention; a fifty percent (50%) undivided interest in rights corresponding to said Patents in foreign countries throughout the world; and a fifty percent (50%) undivided interest in rights to sue for past infringement of said Patents worldwide, together with all claims for damage by reason of past infringement of said Patents, with the right to sue for, and collect the same for *ASSIGNEE'S* own use and enjoyment; all to be held and enjoyed by said *ASSIGNEE*, its successors and assigns, as fully and entirely as the same would have been held and enjoyed by *ASSIGNOR* if this assignment and sale had not been made.

From time to time after the date hereof, at the request of either party hereto, and at the expense of the party so requesting, each of the parties hereto shall execute and deliver to such requesting party such documents and take such other action as such requesting party may reasonably request in order to consummate more effectively the transactions contemplated hereby.

ASSIGNOR further covenants and agrees that, at the time of the execution and delivery of these presents, it possesses full title to the inventions and Patents thereon as earlier identified, and that it has the unencumbered right and authority to make this assignment.

ASSIGNEE hereby authorizes *ASSIGNOR* and their representatives to insert in this Assignment the filing date(s) and Application Number(s) of said patent, utility model, or other application(s) when notified thereof.

IN WITNESS WHEREOF, *ASSIGNOR* and *ASSIGNEE* have hereunto signed this assignment on the dates indicated below.

Executed this 8th day of Nov. , 20 11 .

NOVARTIS AG

BY A. S. Sasin Alexander Sasasin
Authorized signatory

BY Jane-Violet Mantel
Authorized signatory

Witness
Print Name:

S. Bosch
Sonja Bosch

Witness
Print Name:

W. Vogele
W. Vogele

Executed this 8th day of Nov, 20 11 .

ASTEX THERAPEUTICS, LTD.

BY M. M. A. L.S.
HAROLD J. M. COMPANY DIRECTOR

Witness E. M. C.
Print Name: ELMORE FIELD